Skip to content

A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)

A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab in Combination With Methotrexate (MTX) Compared to MTX Alone in Methotrexate- Naive Patients With Active Rheumatoid Arthritis

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00485589
Acronym
FILM
Enrollment
613
Registered
2007-06-13
Start date
2007-06-11
Completion date
2013-08-29
Last updated
2020-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

FILM, RA, anti-CD20, CD20

Brief summary

This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in combination with methotrexate in patients with active rheumatoid arthritis who are naive to methotrexate. Patients will be randomized to receive placebo, ocrelizumab 200mg i.v. or ocrelizumab 500mg i.v. on Days 1 and 15. Repeat courses of i.v. treatment will be administered at weeks 24, 52 and 76. All patients will receive concomitant methotrexate (7.5 mg escalating to 20mg p.o. weekly). The anticipated time on study treatment is 2+ years, and the target sample size is 500+ individuals.

Interventions

DRUGMethotrexate

Oral repeating dose

DRUGOcrelizumab

Intravenous repeating dose

DRUGPlacebo

Intravenous repeating dose

Sponsors

Roche Pharma AG
CollaboratorINDUSTRY
Genentech, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 * Rheumatoid arthritis for 3 months-5 years * Naive to methotrexate * If receiving steroids or NSAIDs, must be on a stable dose for 4 weeks prior to baseline

Exclusion criteria

* Rheumatic autoimmune disease or inflammatory joint disease other than RA * Prior receipt of any biologic therapy for RA * Concurrent treatment with any DMARD

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline in the Modified Total Sharp Score (mTSS) at Week 52Baseline to Week 52The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.

Secondary

MeasureTime frameDescription
Percentage of Participants Without Radiographic Progression (RP) at Week 52Week 52RP was defined as a change from Baseline in the modified Total Sharp Score (mTSS) ≤ 0. The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.
Percentage of Participants With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Week 52Baseline to Week 52Improvement must be seen in tender (68) and swollen (66) joint counts. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation. Improvement must also be seen in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line none \[symptom-free and no arthritis symptoms\] and the extreme right end maximum \[maximum arthritis disease activity\]; patient assessment of pain in the previous 24 hours on a VAS (extreme left end of the line none and the extreme right end unbearable); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C-reactive protein (CRP), or erythrocyte sedimentation rate if CRP was missing.
Percentage of Participants in Disease Activity Score 28 (DAS28) Remission at Weeks 24 and 52Week 24 and Week 52A participant was in DAS28 remission if their DAS28 score \< 2.6). The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where a higher score indicates more disease activity.

Participant flow

Pre-assignment details

The study population comprised adult patients with active rheumatoid arthritis (RA) of at least 3 months' but less than 5 years' duration who were naïve to methotrexate. Additionally, patients were required to be naïve to any biologic therapy for RA prior to enrollment.

Participants by arm

ArmCount
Placebo
Participants received placebo intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, 76, and 78. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
207
Ocrelizumab 200 mg
Participants received ocrelizumab 200 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54 and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
196
Ocrelizumab 500 mg
Participants received ocrelizumab 500 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
202
Total605

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyAdministrative/Other121
Overall StudyAdverse Event3310
Overall StudyDeath220
Overall StudyFailure to return651
Overall StudyInsufficient therapeutic response1031
Overall StudyProtocol Violation100
Overall StudyRefused treatment/did not cooperate102
Overall StudyViolation of selection criteria at entry031
Overall StudyWithdrawal by Subject322

Baseline characteristics

CharacteristicPlaceboOcrelizumab 200 mgOcrelizumab 500 mgTotal
Age, Continuous49.2 Years
STANDARD_DEVIATION 12.43
50.8 Years
STANDARD_DEVIATION 13.17
48.6 Years
STANDARD_DEVIATION 12.29
49.5 Years
STANDARD_DEVIATION 12.66
Sex/Gender, Customized
Female
153 Participants154 Participants161 Participants468 Participants
Sex/Gender, Customized
Male
54 Participants42 Participants41 Participants137 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
EG006
affected / at risk
EG007
affected / at risk
EG008
affected / at risk
EG009
affected / at risk
EG010
affected / at risk
EG011
affected / at risk
deaths
Total, all-cause mortality
0 / 2070 / 100 / 1960 / 120 / 2020 / 62 / 1870 / 92 / 1770 / 111 / 1850 / 6
other
Total, other adverse events
128 / 2074 / 10135 / 1966 / 12144 / 2023 / 635 / 1873 / 932 / 1773 / 1149 / 1855 / 6
serious
Total, serious adverse events
22 / 2070 / 1021 / 1961 / 1231 / 2020 / 611 / 1872 / 92 / 1770 / 114 / 1850 / 6

Outcome results

Primary

Change From Baseline in the Modified Total Sharp Score (mTSS) at Week 52

The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.

Time frame: Baseline to Week 52

ArmMeasureValue (MEAN)Dispersion
PlaceboChange From Baseline in the Modified Total Sharp Score (mTSS) at Week 521.59 Units on a scaleStandard Deviation 4.815
Ocrelizumab 200 mgChange From Baseline in the Modified Total Sharp Score (mTSS) at Week 520.66 Units on a scaleStandard Deviation 4.509
Ocrelizumab 500 mgChange From Baseline in the Modified Total Sharp Score (mTSS) at Week 520.27 Units on a scaleStandard Deviation 2.908
p-value: 0.001Van Elteren's test
p-value: 0.0033Van Elteren's test
Secondary

Percentage of Participants in Disease Activity Score 28 (DAS28) Remission at Weeks 24 and 52

A participant was in DAS28 remission if their DAS28 score \< 2.6). The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where a higher score indicates more disease activity.

Time frame: Week 24 and Week 52

ArmMeasureGroupValue (NUMBER)
PlaceboPercentage of Participants in Disease Activity Score 28 (DAS28) Remission at Weeks 24 and 52Week 249.7 Percentage of participants
PlaceboPercentage of Participants in Disease Activity Score 28 (DAS28) Remission at Weeks 24 and 52Week 527.2 Percentage of participants
Ocrelizumab 200 mgPercentage of Participants in Disease Activity Score 28 (DAS28) Remission at Weeks 24 and 52Week 2419.9 Percentage of participants
Ocrelizumab 200 mgPercentage of Participants in Disease Activity Score 28 (DAS28) Remission at Weeks 24 and 52Week 5227 Percentage of participants
Ocrelizumab 500 mgPercentage of Participants in Disease Activity Score 28 (DAS28) Remission at Weeks 24 and 52Week 2418 Percentage of participants
Ocrelizumab 500 mgPercentage of Participants in Disease Activity Score 28 (DAS28) Remission at Weeks 24 and 52Week 5228 Percentage of participants
Secondary

Percentage of Participants With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Week 52

Improvement must be seen in tender (68) and swollen (66) joint counts. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation. Improvement must also be seen in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line none \[symptom-free and no arthritis symptoms\] and the extreme right end maximum \[maximum arthritis disease activity\]; patient assessment of pain in the previous 24 hours on a VAS (extreme left end of the line none and the extreme right end unbearable); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C-reactive protein (CRP), or erythrocyte sedimentation rate if CRP was missing.

Time frame: Baseline to Week 52

ArmMeasureGroupValue (NUMBER)
PlaceboPercentage of Participants With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Week 52ACR5039.6 Percentage of participants
PlaceboPercentage of Participants With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Week 52ACR2057.5 Percentage of participants
PlaceboPercentage of Participants With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Week 52ACR7020.3 Percentage of participants
Ocrelizumab 200 mgPercentage of Participants With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Week 52ACR5060.7 Percentage of participants
Ocrelizumab 200 mgPercentage of Participants With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Week 52ACR2073 Percentage of participants
Ocrelizumab 200 mgPercentage of Participants With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Week 52ACR7038.3 Percentage of participants
Ocrelizumab 500 mgPercentage of Participants With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Week 52ACR5054.5 Percentage of participants
Ocrelizumab 500 mgPercentage of Participants With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Week 52ACR7038 Percentage of participants
Ocrelizumab 500 mgPercentage of Participants With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Week 52ACR2071 Percentage of participants
Secondary

Percentage of Participants Without Radiographic Progression (RP) at Week 52

RP was defined as a change from Baseline in the modified Total Sharp Score (mTSS) ≤ 0. The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.

Time frame: Week 52

ArmMeasureValue (NUMBER)
PlaceboPercentage of Participants Without Radiographic Progression (RP) at Week 5251 Percentage of participants
Ocrelizumab 200 mgPercentage of Participants Without Radiographic Progression (RP) at Week 5266.3 Percentage of participants
Ocrelizumab 500 mgPercentage of Participants Without Radiographic Progression (RP) at Week 5268.8 Percentage of participants

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026